OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$4.08
0.09 (2.26%)
▲
5d:
-0.49%
30d:
+2.51%
90d:
-12.07%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $4.08, which is considered extended relative to its 30-day fair value range of $3.87 to $4.05.
Technical Outlook: Technically, OBIO is showing sideways momentum. The price is approaching resistance at $4.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.17 (+198.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OBIO is showing sideways momentum. The price is approaching resistance at $4.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.17 (+198.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.87 -
$4.05
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 198.2% below Wall St target ($12.17)
Trading Range Analysis
30-Day Trading Range
$3.87 -
$4.05
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.53
(13.1%)
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.14
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.80
Wall Street Target
$12.17
(+198.2%)
Revenue Growth (YoY)
-87.3%
Profit Margin
-167.0%
Share & Embed Analysis
Last updated: June 23, 2026 6:09 AM ET
Data refreshes hourly during market hours. Next update: 7:09 AM
Data refreshes hourly during market hours. Next update: 7:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Hochman
BUY
10000 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 67 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 61 BUY |
